Flecainide to prevent atrial arrhythmia after patent foramen ovale closure Rationale and design of the randomized AFLOAT study.
Marie Hauguel-MoreauPaul GuedeneyClaire DauphinVincent AuffretEloi MarijonPhilippe AldebertJean-Michel ClercFarzin BeyguiMeyer ElbazWissam Abi KhalilAntoine Da CostaJean-Christophe MaciaSimon ElhadadGuillaume CaylaDelphine BrugierJohanne SilvainNadjib HammoudiGuillaume DuthoitEric VicautGilles Montalescotnull nullPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
AFLOAT is the first trial to test the hypothesis that a short treatment with oral Flecainide can prevent the new-onset of atrial arrhythmia after PFO closure. Clinical trial registration: NCT05213104 (clinicaltrials.gov).